Early trial data demonstrated that Wegovy, which has been shown to help patients lose an average of 15% of their weight, also reduced incidence of heart attack, stroke or death from heart disease by 20%.
This implies that at least some of the relationship between obesity and heart issues is not the result of obesity but both being caused by low semaglutide.
This implies that at least some of the relationship between obesity and heart issues is not the result of obesity but both being caused by low semaglutide.